ELCC 2022 | IFCT-1803 LORLATU cohort: real-world evidence supporting lorlatinib in ALK+ NSCLC

Nicolas Girard, MD, PhD, Institut Curie, Paris, France, discusses the results of the IFCT-1803 LORLATU cohort (NCT03727477) assessing treatment sequencing, and lorlatinib safety and efficacy in patients with ALK- and ROS1-positive non-small cell lung cancer (NSCLC). The real-world evidence demonstrated lorlatinib provides a notable clinical benefit in heavily pretreated patients with ALK-positive NSCLC. This interview took place during the virtual European Lung Cancer Congress 2022.